Watch JSPR. Know when insiders buy.
One email the day a filing lands. Free.
JSPR
Jasper Therapeutics, Inc.
0.62
−0.02 −2.52%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $20.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$31.8MNET CASH —52W 0.34 – 2.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$9.2M | −$2.8M | — | -0.10 | −$6.9M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$11M | −$1.2M | — | -0.04 | −$14.5M | — | — | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$15.8M | −$9.1M | — | 0.23 | −$21.9M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$19.2M | −$18.7M | — | -1.13 | −$17M | — | — | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$27.1M | −$26.7M | — | -1.74 | −$15.5M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$21.8M | −$21.2M | — | -1.41 | −$22.8M | — | — | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$25.3M | −$24.3M | — | -1.64 | −$21.1M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$19.9M | −$18.6M | — | -1.24 | −$14.1M | — | — | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$16M | −$14.6M | — | -0.97 | −$11.7M | — | — | Aug 13 |
| Q1 2024 · Mar 31 | — | — | — | −$15.1M | −$13.7M | — | -1.03 | −$15.7M | — | — | May 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$17.7M | −$16.6M | — | -1.50 | −$16.5M | — | — | Feb 28 |
| Q3 2023 · Sep 30 | — | — | — | −$19.4M | −$17.5M | — | -1.60 | −$12M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$83.9M | −$75.8M | — | -3.95 | −$77.2M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$76.2M | −$71.3M | — | -4.89 | −$62.6M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$68.9M | −$64.5M | — | -6.18 | −$52.1M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$51.2M | −$37.7M | — | -10.33 | −$45.9M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$36.8M | −$30.6M | — | -2.69 | −$33.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$20.7M | −$31.7M | — | -5.17 | −$18.3M | — | — | — | — |
Every number comes from Jasper Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.